Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs), developed by longtime ...

Senju Pharma has launched a new drug for dry eye disease (DED) in Japan, Avarept, which is the first drug in the TRPV1 ...

For many life sciences start-ups, bringing on a GC early can be a strategic advantage. An experienced GC can help shape the ...

The FDA has approved orforglipron, under the Foundayo trade name, in just 50 days, thanks to a fast track review under the ...

The only gene-editing therapy approved for beta-thalassaemia at present is Vertex Pharma's CRISPR-based Casgevy ...

Avalyn's inhaled therapies use a nebuliser technology developed by PARI. Boston-based biotech Avalyn Pharma is the latest to hop on the IPO train, filing to list on the Nasdaq and raise funds for late ...

Healthcare in the UK is at an inflection point. To ensure the NHS remains fit for the future, the Government launched its 10-Year Health Plan for England last year, setting out strong ambitions around ...

His teams are trained to read where it will be three passes from now. In Formula 1, race strategy is no longer a gut call at ...

The FDA has ramped up the pressure on Amgen to withdraw Tavneos for a rare vasculitis condition from the market, with a ...

AZ has yet to file for approval of Imfinzi in the frontline setting for earlier-stage HCC, despite its well-established role ...

The Beijing biotech has been set up to tap into the growing interest in macrocyclic peptides as an emerging treatment ...

PHARMAP 2026 provides the platform for a key industry conversation: how leading pharmaceutical companies are further ...